Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatmen
资讯
2026-01-06
Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera
NDA Includes 52-Week Data from Phase 3 VERIFY Study, W...